广西医科大学第一附属医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma54 篇牵头论文牵头 5 项开放试验
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma4 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma134 篇牵头论文
- 胃癌Stomach cancer46 篇牵头论文
- 肝母细胞瘤Hepatoblastoma1 篇牵头论文
- 脊索瘤Chordoma0 篇牵头论文
- 骨肉瘤Osteosarcoma37 篇牵头论文
- 神经母细胞瘤Neuroblastoma3 篇牵头论文
- 尤文肉瘤Ewing sarcoma1 篇牵头论文
- 多发性骨髓瘤Multiple myeloma11 篇牵头论文
- 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis3 篇牵头论文
- β 地中海贫血Beta thalassaemia25 篇牵头论文牵头 1 项开放试验
- 血友病 AHaemophilia A2 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder3 篇牵头论文
- 重症肌无力Myasthenia gravis5 篇牵头论文
- 烟雾病Moyamoya disease4 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis11 篇牵头论文
- 大动脉炎Takayasu arteritis2 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy2 篇牵头论文
- 白塞病Behçet disease0 篇牵头论文
- IgA 肾病IgA nephropathy4 篇牵头论文
- 成骨不全症Osteogenesis imperfecta1 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis2 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis1 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis0 篇牵头论文
未列出的收录疾病:视网膜母细胞瘤、胃肠道间质瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、IgG4相关性疾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 54 篇,占 2.3%。
南宁有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
- 分期
- III期
- 开始
- 2026-03
- 登记号
- NCT07459296
年龄 18 岁 至 70 岁(登记的条件)
牵头:广西医科大学第一附属医院南宁
- 正在招募Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- 分期
- 不分期
- 开始
- 2023-06
- 登记号
- NCT05892354
年龄 18 岁 至 70 岁(登记的条件)
牵头:广西医科大学第一附属医院;另有 13 家列出的医院为研究中心南宁、南昌、广州、杭州、柳州、桂林、梧州、海口、福州
- 即将招募Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
- 分期
- II期
- 开始
- 2026-09
- 登记号
- NCT07303283
年龄 18 岁 至 65 岁(登记的条件)
牵头:广西医科大学第一附属医院南宁
- 即将招募Impacted Tooth Management and Osteoradionecrosis Risk in NPC
- 分期
- 不分期
- 开始
- 2026-08
- 登记号
- NCT07764887
年龄 18 岁 至 75 岁(登记的条件)
牵头:广西医科大学第一附属医院;另有 6 家列出的医院为研究中心中山、南宁、柳州、桂林、梧州
- 即将招募Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
- 分期
- II期
- 开始
- 2024-11
- 登记号
- NCT06680115
年龄 18 岁 至 未注明(登记的条件)
牵头:广西医科大学第一附属医院南宁
- 正在招募IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
- 分期
- III期
- 开始
- 2024-01
- 登记号
- NCT05941741
年龄 18 岁 至 70 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 2 家列出的医院为研究中心南宁、南昌、广州
- 正在招募Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
- 分期
- 未注明
- 开始
- 2024-05
- 登记号
- NCT06445088
年龄未注明(登记的条件)
牵头:中山大学肿瘤防治中心;另有 4 家列出的医院为研究中心中山、南宁、广州、梧州、福州
- 正在招募Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- 分期
- III期
- 开始
- 2022-04
- 登记号
- NCT05340491
年龄 18 岁 至 70 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳
- 正在招募PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
- 分期
- III期
- 开始
- 2020-03
- 登记号
- NCT03907826
年龄 18 岁 至 70 岁(登记的条件)
牵头:中山大学肿瘤防治中心;另有 10 家列出的医院为研究中心上海、南宁、南昌、厦门、广州、成都、杭州、武汉、福州、西安、贵阳
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文54
- BHLHE40-mediated upregulation of CAV1 decreases the radiosensitivity of nasopharyngeal carcinoma.
- Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study.
- Clinical features and CTA imaging of radiation-induced carotid pseudoaneurysms in nasopharyngeal carcinoma.
- Baseline audiometric assessment of newly diagnosed nasopharyngeal carcinoma patients: a multicentre cross-sectional study.
- Radiomics based on dual-energy CT for noninvasive prediction of cervical lymph node metastases in patients with nasopharyngeal carcinoma.
- The potential value of IVIM MR for radiation-related hypothyroidism in nasopharyngeal carcinoma.
- Effect of HSPA 8 on the biological function of NPC cells and its mechanism.
- Carboxylesterase 4A Inhibits the Malignant Biological Behavior of Nasopharyngeal Carcinoma via the PI3K/AKT Pathway.
- Oncogenic and immunological roles of RACGAP1 in pan-cancer and its potential value in nasopharyngeal carcinoma.
- Establishment of a visualized mouse orthotopic xenograft model of nasopharyngeal carcinoma.
- Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.
- Immune checkpoint inhibitor combined with chemotherapy versus chemotherapy alone in the first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis of random controlled trials.
- Circulating tumor cells: a valuable indicator for locally advanced nasopharyngeal carcinoma.
- Prediction of severe radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma using the combined systemic immune-inflammatory index and prognostic nutritional index.
- The prognostic implications of radiologic extranodal extension in the lymph nodes of patients with nasopharyngeal cancer.
- Prognostic value of sarcopenia in the patients with locally advanced nasopharyngeal carcinoma.
- New T staging recommendations for recurrent nasopharyngeal carcinoma.
- Study on carotid artery stenosis after radiotherapy for nasopharyngeal carcinoma.
- Effects of concurrent chemoradiotherapy with or without Endostar on the regression of retropharyngeal lymph node and prognosis of patients with locally advanced nasopharyngeal carcinoma: a retrospective study.
- LncRNA HOTAIRM1 promotes radioresistance in nasopharyngeal carcinoma by modulating FTO acetylation-dependent alternative splicing of CD44.
- Quantitative parameter analysis of pretreatment dual-energy computed tomography in nasopharyngeal carcinoma cervical lymph node characteristics and prediction of radiotherapy sensitivity.
- Potential predictive value of IVIM MR for xerostomia in nasopharyngeal carcinoma.
- The feasibility of level Ib-sparing intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma and high-risk factors classified based on the International Guideline.
- Combined pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio predicts survival and prognosis in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
- Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: a randomized controlled trial.
- Risk factors and the nomogram model for malnutrition in patients with nasopharyngeal carcinoma.
- Taxonomy and anticancer potential of Streptomyces niphimycinicus sp. nov. against nasopharyngeal carcinoma cells.
- Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
- Nomogram to Predict Long-Term Overall Survival and Cancer-Specific Survival of Radiotherapy Patients with Nasopharyngeal Carcinoma.
- Scheduling radiotherapy for patients with nasopharyngeal carcinoma in the corresponding time window can reduce radiation-induced oral mucositis: A randomized, prospective study.
- WDHD1 is over-expressed in nasopharyngeal carcinoma and may control the expression of ITGAV.
- Exploring the expression of SNHG1 and its effect on the PI3K-AKT axis in nasopharyngeal cancer.
- Quality evaluation index development for nutritional management in patients with nasopharyngeal carcinoma during peri-radiotherapy.
- The application of the PDCA cycle in the nutritional management of patients with nasopharyngeal carcinoma.
- Performance of Pretreatment MRI-Based Radiomics in Recombinant Human Endostatin Plus Concurrent Chemoradiotherapy Response Prediction in Nasopharyngeal Carcinoma: A Retrospective Study.
- Analysis of the risk of death and clinical management for nasal or nasopharyngeal bleeding occurring after radiotherapy for nasopharyngeal carcinoma.
- Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis.
- Clinical value and potential mechanisms of BUB1B up-regulation in nasopharyngeal carcinoma.
- Development and validation of an MRI-based radiomic model for predicting overall survival in nasopharyngeal carcinoma patients with local residual tumors after intensity-modulated radiotherapy.
- Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.
- Nomogram Based on Clinical and Radiomics Data for Predicting Radiation-induced Temporal Lobe Injury in Patients with Non-metastatic Stage T4 Nasopharyngeal Carcinoma.
- Potential Molecular Mechanism of Upregulated Aryl Hydrocarbon Receptor Nuclear Translocator 2 in Nasopharyngeal Carcinoma.
- Predicting Nomogram for Severe Oral Mucositis in Patients with Nasopharyngeal Carcinoma during Intensity-Modulated Radiation Therapy: A Retrospective Cohort Study.
- Downregulation of MicroRNA-1 and Its Potential Molecular Mechanism in Nasopharyngeal Cancer: An Investigation Combined with In Silico and In-House Immunohistochemistry Validation.
- Downregulated miR-150-5p in the Tissue of Nasopharyngeal Carcinoma.
- FOXM1 regulates glycolysis in nasopharyngeal carcinoma cells through PDK1.
- Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
- Prognostic value of the cervical lymph node necrosis ratio in nasopharyngeal carcinoma.
- Long-term efficacy and adverse reactions of IMRT combined with Endostar versus IMRT combined with chemotherapy for locally advanced nasopharyngeal carcinoma: a retrospective study.
- Tubulin polymerization promoting protein family member 3 (TPPP3) overexpression inhibits cell proliferation and invasion in nasopharyngeal carcinoma.
- Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma.
- miRNAs derived from circulating small extracellular vesicles as diagnostic biomarkers for nasopharyngeal carcinoma.
- Radiation Therapy-Induced Changes of the Nasopharyngeal Commensal Microbiome in Nasopharyngeal Carcinoma Patients.
- Prognostic nomogram to predict the distant metastasis after intensity-modulated radiation therapy for patients with nasopharyngeal carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)22
- Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
- Impacted Tooth Management and Osteoradionecrosis Risk in NPC
- Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
- Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
- Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
- Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma
- Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
- Hearing Impairment of Nasopharyngeal Carcinoma
- PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
- Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
- A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
- IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
- Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
- PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
- Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
- Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
- Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
- Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images
- A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis
- Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
PubMed 以外找到的论文(未计入)56
- 1393P MiPEP133 promoting radiosensitivity of nasopharyngeal carcinoma via downregulation of ACL-mediated DNA break
- 710P Mapping the disparity of nasopharyngeal carcinoma burden across 34 provinces in China, 1990-2040, forecasts with scenarios simulation using deep-learning algorithm
- Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)
- Additional file 1 of Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study
- CACA guidelines for holistic integrative management of adolescent and childhood nasopharyngeal carcinoma
- Induction chemotherapy with or without toripalimab followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicenter, open-label, randomized, controlled, phase 2 trial.
- Muscle-specific MRI grading of soft tissue involvement provides additional prognostic value beyond skull base criteria in nasopharyngeal carcinoma: a retrospective study
- The Impact of Air Cavity Correction on Optimization Convergence Error in Intensity-Modulated Radiation Therapy Planning for Nasopharyngeal Carcinoma
- Updated efficacy, safety and biomarker analysis of a phase 2 study of LBL-007 (alcestobart, an anti-LAG-3 mAb) combined with tislelizumab (an anti–PD-1 mAb) and chemotherapy in previously untreated recurrent or metastatic nasopharyngeal car
- Acetyl-CoA acyltransferase 1 is a potential tumor suppressor gene associated with immune cell infiltration in nasopharyngeal carcinoma
- Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.
- Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial.
- Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.
- Predicting the risk of sarcopenia in Nasopharyngeal Carcinoma patients: Development and assessment of a new predictive nomogram
- Prognostic Analysis of Nonmetastatic Nasopharyngeal Carcinoma in Older Patients Undergoing Intensity‐Modulated Radiotherapy
- Additional file 1 of Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway
- Additional file 3 of Knockdown of TFRC suppressed the progression of nasopharyngeal carcinoma by downregulating the PI3K/Akt/mTOR pathway
- CACA guidelines for holistic integrative management of nasopharyngeal carcinoma
- Chemotherapy combined with anlotinib, toripalimab and stereotactic radiotherapy in oligo-metastatic nasopharyngeal carcinoma: A prospective, multicenter phase II clinical study.
- Efficacy and safety of immunonutrition in preventing oral mucositis during concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
- Exploring the Clinical Characteristics and Survival of Early-Onset and Late-Onset Nasopharyngeal Carcinoma
- Icariside II targets in vitro MAPK and PI3K/Akt signaling in human nasopharyngeal carcinoma cells to induce apoptotic death and suppress proliferation
- Impact of radiotherapy for nasopharyngeal carcinoma on carotid stenosis risk: a meta-analysis
- Perspective Chapter: Modulation of Latent to Lytic Cycle Infection Switch and Its Implication in EBV Mediated Tumorigenicity
- Potential Predictive Value of Intravoxel Incoherent Motion Magnetic Resonance for Xerostomia of Nasopharyngeal Carcinoma
- Surgical treatment of oligometastatic nasopharyngeal carcinoma
- The Feasibility of Level Ib Sparing Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma Patients with High-Risk Factors: Based on International Guideline
- WITHDRAWN: Effect of modified Baduanjin exercise on nutritional status in patients with nasopharyngeal carcinoma: A randomized controlled trial
- Additional file 1 of A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma
- Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 1 of Comparing the efficacy and safety of cisplatin and other platinum-based chemotherapies in locally advanced nasopharyngeal carcinoma: a systematic review and meta-analysis
- Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Development and validation of an MRI-based radiomic model for predicting overall survival in nasopharyngeal carcinoma patients with local residual tumors after intensity-modulated radiotherapy
- Additional file 2 of Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma
- Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Analysis of hnRNP K Expression and Relevance for Clinical Outcomes in Hepatocellular carcinoma
- Establishment of a visualized mouse orthotopic model of nasopharyngeal carcinoma.
- Factors influencing out of pocket ratio to CPS among NPC patients in Guangxi: 2014-2020
- Myocardin immunohistochemistry index is associated with clinical prognosis in nasopharyngeal carcinoma: a clinical practice-based cohort study
- Recombinant human endostatin combined with intensity-modulated radiotherapy in low-risk locoregionally advanced nasopharyngeal carcinoma: A phase II, randomized, multicenter clinical trial.
- The performance of pretreatment MR-based radiomics in Recombinant human endostatin plus concurrent chemoradiotherapy response prediction in nasopharyngeal carcinoma: A primary study
- Upregulation of ITGAV and the underlying mechanisms in nasopharyngeal carcinoma
- 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results
- Cucurbitacin B as a Chinese Medicine Monomer Inhibits Cell Proliferation, Invasion, and Migration in Nasopharyngeal Carcinoma
- Diagnosis and Therapy of Nasopharyngeal Carcinoma
- Endostar combined with intensity-modulated radiotherapy in low-risk local advanced nasopharyngeal carcinoma: A phase II, randomized, multicentric clinical trial.
- Genome-Scale CRISPR-Cas9 Knockout Screening in Nasopharyngeal Carcinoma for Radiosensitive and Radioresistant Genes
- Is the Equivalent Uniform Dose Model Being Used Properly? Impact of Dose Distribution on Parameter and Predictive Ability
- Maintenance intervention to improve survival in patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment: A prospective multicenter randomized controlled clinical study.
- Potential Role of The Upregulation of The Zinc Finger Protein of The Cerebellum 2 In Nasopharyngeal Carcinoma
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 4 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文4
- Macrophage Infiltration and ITGB2 Expression in ESCC: A Novel Correlation.
- Comprehensive analysis of clinical features, mRNA splicing, and immunological role of REEP5 in esophageal squamous cell carcinoma.
- Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis.
- Overexpression of cyclin-dependent kinase 1 in esophageal squamous cell carcinoma and its clinical significance.
PubMed 以外找到的论文(未计入)12
- Research on the Expression and Mechanism of LRRC8D in Esophageal Squamous Cell Carcinoma
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Exosomal circRNA FNDC3B promotes the progression of esophageal squamous cell carcinoma by sponging miR-490-5p and regulating thioredoxin reductase 1 expression
- Significance of Sarcopenia and the Neutrophil-to-Lymphocyte Ratio in Elderly Patients with Esophageal Squamous Cell Carcinoma
- The Clinical Significance of Forkhead Box M1 in Esophageal Squamous Cell Carcinoma Tissues: A Study Based on In-house Immunohistochemistry, RNA-sequencing, and Data Mining
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
- Long non-coding RNA BCAR4 aggravated proliferation and migration in esophageal squamous cell carcinoma by negatively regulating p53/p21 signaling pathway
- MicroRNA-624-mediated ARRDC3/YAP/HIF1α axis enhances esophageal squamous cell carcinoma cell resistance to cisplatin and paclitaxel
- Overexpression of UBE2C in Esophageal Squamous Cell Carcinoma Tissues and Molecular Analysis
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 134 篇,占 0.9%。
- 牵头的开放试验
- 0
- 正在或即将招募
南宁有 5 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
- 分期
- I期
- 开始
- 2026-04
- 登记号
- NCT07478302
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心南宁、福州
- 正在招募Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- 分期
- 未注明
- 开始
- 2025-09
- 登记号
- NCT07170345
年龄 18 岁 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州
- 即将招募The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- 分期
- 未注明
- 开始
- 2026-07
- 登记号
- NCT07724951
年龄 18 岁 至 未注明(登记的条件)
牵头:复旦大学附属中山医院;另有 6 家列出的医院为研究中心上海、南宁、哈尔滨、广州、青岛
- 即将招募TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- 分期
- II期
- 开始
- 2025-12
- 登记号
- NCT07350070
年龄 18 岁 至 75 岁(登记的条件)
牵头:华中科技大学同济医学院附属同济医院;另有 4 家列出的医院为研究中心南宁、武汉、济南、福州、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文134
- Incorporating new criteria can improve the ability of CEUS LI-RADS to differentiate HCC from non-HCC malignancies.
- NSUN3-Mediated ROS Accumulation Promotes Hepatocellular Carcinoma Proliferation and Activates PI3K/AKT Pathway.
- Time-dependent diffusion-weighted MRI discriminates hepatocellular carcinoma from intrahepatic cholangiocarcinoma: A prospective animal model study.
- Time-dependent diffusion MRI combined with enhanced MRI and clinical indicators for preoperative prediction of CK19 expression status in hepatocellular carcinoma: a prospective study.
- A Phototherapy Nanosensitizer-Unlocked Multihit Strategy to Inhibit Tumor Stemness and Potentiate Sorafenib Response in Hepatocellular Carcinoma.
- Development of a model combining CEUS LI-RADS and clinical features for predicting glypican-3 expression in hepatocellular carcinoma.
- Development and validation of a combined radiomic and clinical model based on contrast-enhanced ultrasound for preoperative prediction of CK19-positive hepatocellular carcinoma.
- Radiomics-based Machine Learning for Predicting Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
- An analysis of the clinical significance of the TKI-resistant gene ZNF687 for hepatocellular carcinoma patients.
- Predictive value of intra-hepatectomy ICGR15 of the remnant liver for post-hepatectomy liver failure in hemi-hepatectomy: a prospective study.
- Donafenib activates the p53 signaling pathway in hepatocellular carcinoma, induces ferroptosis, and enhances cell apoptosis.
- Silencing NCAPD3 Inhibits Tumor Growth and Metastasis in Hepatocellular Carcinoma by Suppressing PI3K-AKT Signalling Pathway.
- Novel biomarker in hepatocellular carcinoma: Stearoyl-CoA desaturase 1.
- HBV-induced N6 methyladenosine modification of PARP1 enhanced AFB1-related DNA damage and synergistically contribute to HCC.
- Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma.
- A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1/PRDX1 as therapeutic targets.
- Stereotactic body radiation therapy combined with cadonilimab and lenvatinib in the treatment of hepatocellular carcinoma with Vp3 or Vp4 portal vein tumor thrombus: a prospective, multicenter, single-arm, phase II clinical trial.
- The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection.
- Potential regulatory mechanism of overexpression of phosphatidylinositol glycan anchor biosynthesis class U on the glycolytic pathway in hepatocellular carcinoma.
- FAHD1-mediated pyruvate metabolism in hepatocellular carcinoma: Multi-omics and causal genetic evidence.
- Structural characterization and functional role of SLC7A6 in GSSG transport and Ferroptosis regulation.
- Serum Alpha-Fetoprotein-Tumor Size Ratio as a Prognostic Marker After Hepatic Resection for Primary Hepatocellular Carcinoma: Propensity Score Matched Retrospective Cohort Study.
- Development and Validation of an Extra Spindle Pole Bodies-like 1-Based Diagnostic and Prognostic Model for Hepatitis B Virus-Related Hepatocellular Carcinoma: Retrospective Cohort Study.
- Impact of pre-examination video education in Gd-EOB-DTPA-enhanced liver MRI: A comparative study.
- Hsa_circ_0016662 acts as a prognostic biomarker and promotes the progression of hepatocellular carcinoma via autophagy regulation.
- Proteomic and metabolomic analysis of platelet related samples reveals energy metabolism disorders in hepatocellular carcinoma.
- AP5Z1 affects hepatocellular carcinoma growth and autophagy by regulating PTEN ubiquitination and modulating the PI3K/Akt/mTOR pathway.
- Integrating single-cell and bulk RNA sequencing data to characterize the heterogeneity of glycan-lipid metabolism polarization in hepatocellular carcinoma.
- Spleen volume after stage-I associated liver partition and portal vein ligation for staged hepatectomy predicts future liver remnant.
- MRI-Based Topology Deep Learning Model for Noninvasive Prediction of Microvascular Invasion and Assisting Prognostic Stratification in HCC.
- Transformer model based on Sonazoid contrast-enhanced ultrasound for microvascular invasion prediction in hepatocellular carcinoma.
- Balancing Image Quality and Iodine Intake: Insights from CT Spectral Imaging of the Portal Vein.
- Deubiquitinase-associated mRNA signature model predicts prognosis and influences the immune microenvironment in patients with hepatocellular carcinoma: An observational study.
- Overexpression of PLK1 Molecule Following Incomplete Thermal Ablation Promotes the Proliferation and Invasion of Residual Hepatocellular Carcinoma.
- Heterogeneity of tumor-associated neutrophils in hepatocellular carcinoma.
- Nitidine chloride inhibits the progression of hepatocellular carcinoma by suppressing IGF2BP3 and modulates metabolic pathways in an m6A-dependent manner.
- METTL3/IGF2BP2 stabilizes IQGAP3 via m6A modification to drive HCC metastasis through TGF-β/Smad signaling and EMT.
- Exploring the level of metabolic reprogramming and the role of prognostic factor SF3A3 in hepatocellular carcinoma through integrated single-cell landscape analysis.
- Epigallocatechin Gallate Derivative Y6 Reverses Oxaliplatin Resistance in Hepatocellular Carcinoma via Targeting the MiR-338-3p/HIF-1α/TWIST Axis to Inhibit EMT.
- EXOSC3 knockdown induces G1/S phase arrest to suppress hepatocellular carcinoma cell proliferation.
- Atorvastatin negatively regulates MAPK pathway in vitro to inhibit proliferation, migration, and invasion of hepatocellular carcinoma cells.
- Fatty acid-binding proteins as potential biomarkers for human cancer prognosis.
- Exploreing the potential mechanism of Aitongxiao formula inhibiting hepatocellular carcinoma in vitro and in vivo based on network Pharmacology.
- Cystathionine gamma-lyase as an inflammatory factor and its link with immune inflammation in hepatitis B virus-related liver disease.
- The LncRNA lnc-POTEM-4:14 promotes HCC progression by interacting with FOXK1.
- Comprehensive Pan-Cancer Analysis and Functional Studies Reveal SLC2A6 as a Ferroptosis Modulator in Hepatocellular carcinoma.
- Liver resection in stage 0-A HCC in segments 7/8: a propensity-matched analysis comparing open, laparoscopic, and robotic approach.
- 2-Dodecyl-6-Methoxycyclohexa-2,5-Diene-1,4-Dione from Averrhoa carambola L. roots: Suppressing hepatocellular carcinoma progression through ROS accumulation and p53 pathway-mediated apoptosis.
- Diagnostic performance of serum origin recognition complex subunit 1 protein for hepatitis B virus-related hepatocellular carcinoma.
- Robotic versus open hepatectomy for large(≥ 5 cm) hepatocellular carcinoma: A large volume center, propensity score matched study.
- Intra-individual comparison of Sonazoid contrast-enhanced ultrasound and SonoVue contrast-enhanced ultrasound in diagnosing hepatocellular carcinoma.
- Role of CCR1/5/7 in hepatocellular carcinoma: a study on prognostic evaluation, molecular subtyping, and association with immune infiltration.
- RBCK1 overexpression is associated with immune cell infiltration and poor prognosis in hepatocellular carcinoma.
- Prediction of prognosis of patients with hepatocellular carcinoma based on immune-related score.
- M2 tumor-associated macrophages and CXCL2 induce lipid remodeling in hepatocellular carcinoma cell lines.
- Prognostic value of geriatric nutritional risk index and prognostic nutritional index in hepatocellular carcinoma.
- Value of the Stretched Exponential and Fractional-order Model in Differentiating Hepatocellular from Intrahepatic Cholangiocarcinoma.
- Potential Value of the Stretched Exponential and Fractional Order Calculus Model in Discriminating Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: An Animal Experiment of Orthotopic Xenograft Nude Mice.
- Exploring the impact of insufficient thermal ablation on hepatocellular carcinoma: NDST2 overexpression mechanism and its role in facilitating growth and invasion of residual cancer cells.
- A Novel Prognostic Model of Hepatocellular Carcinoma per Two NAD+ Metabolic Synthesis-Associated Genes.
- The Value of CEUS LI-RADS combined with AFP in early diagnosis of hepatocellular carcinoma in low- and high-risk patients.
- Clinical Significance of Upregulation of EZH1 Expression in Hepatocellular Carcinoma Tissues.
- Letter to Dr. Wang Jian and his team about our paper "Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study" published on "La radiologi
- Identification and validation of ATP6V1G1-regulated phosphorylated proteins in hepatocellular carcinoma.
- Nomogram based on the neutrophil-to-lymphocyte ratio and MR diffusion quantitative parameters for predicting Ki67 expression in hepatocellular carcinoma from a prospective study.
- Analysis of clinicopathologic and imaging features of dual-phenotype hepatocellular carcinoma.
- A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
- CEUS LI-RADS in Combination With the Serum Biomarker-Based ASAP Model Improves the Diagnostic Performance of HCC in High-Risk Patients.
- Performance of current versus modified CEUS LI-RADS in the diagnosis of non-hepatocellular carcinoma malignancies.
- SART3, regulated by p53, is a biomarker for diagnosis, prognosis and immune infiltration in hepatocellular carcinoma.
- Correlation Between Serum ESPL1 and Hepatitis B Virus-related Hepatocellular Carcinoma Histological Grade: A Chinese Single-center Case-control Study.
- Differences between CEUS LI-RADS and CECT LI-RADS in the diagnosis of focal liver lesions in patients at risk for HCC.
- Development and validation of a nomogram for survival prediction in hepatocellular carcinoma after partial hepatectomy.
- The investigation on the hypercoagulability of hepatocellular carcinoma-related cerebral infarction with thromboelastography.
- Advances in SEMA3F regulation of clinically high-incidence cancers.
- Clinical Implication of E2F Transcription Factor 1 in Hepatocellular Carcinoma Tissues.
- Highly expressed carbohydrate sulfotransferase 11 correlates with unfavorable prognosis and immune evasion of hepatocellular carcinoma.
- Nucleoporin 107 is a prognostic biomarker in hepatocellular carcinoma associated with immune infiltration.
- A Retrospective Study of Long-Term Clinical Outcomes in Patients with Chronic Hepatitis C Treated with Interferon and Ribavirin.
- Case report: hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib for conversion therapy of colorectal cancer liver metastases.
- 4-Methoxydalbergione Elicits Anticancer Effects by Upregulation of GADD45G in Human Liver Cancer Cells.
- Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma.
- Comparison of the Feasibility and Diagnostic Performance of ACR CEUS LI-RADS and a Modified CEUS LI-RADS for HCC in Examinations Using Sonazoid.
- Can Modifications of LR-M Criteria Improve the Diagnostic Performance of Contrast-Enhanced Ultrasound LI-RADS for Small Hepatic Lesions up to 3 cm?
- Nomogram based on clinical and preoperative CT features for predicting the early recurrence of combined hepatocellular-cholangiocarcinoma: a multicenter study.
- Pre-operative MRI features predict early post-operative recurrence of hepatocellular carcinoma with different degrees of pathological differentiation.
- Prognostic value and potential molecular mechanism of ITGB superfamily members in hepatocellular carcinoma.
- High expression of ENPP2 is an independent predictor of poor prognosis in liver cancer.
- Nomogram to predict the prognosis of patients with AFP-negative hepatocellular carcinoma undergoing chemotherapy: A SEER based study.
- A radiomics model based on magnetic resonance imaging to predict cytokeratin 7/19 expression and liver fluke infection of hepatocellular carcinoma.
- Robust analysis of a novel PANoptosis-related prognostic gene signature model for hepatocellular carcinoma immune infiltration and therapeutic response.
- Outer dynein arm docking complex subunit 2 polymorphism rs7893462 modulates hepatocellular carcinoma susceptibility and can serve as an overall survival biomarker for hepatitis B virus-related hepatocellular carcinoma after hepatectomy: a c
- Identify GADD45G as a potential target of 4-methoxydalbergione in treatment of liver cancer: bioinformatics analysis and in vivo experiment.
- Gd-EOB-DTPA-enhanced magnetic resonance imaging may help identify patients with hepatocellular carcinoma eligible for treatment targeted at RAF1.
- Diagnostic performance and interreader agreement of CEUS LI-RADS in ≤ 30 mm liver nodules with different experienced radiologists.
- Gender disparity in hepatocellular carcinoma recurrence after curative hepatectomy.
- The expression characteristics and clinical significance of ACP6, a potential target of nitidine chloride, in hepatocellular carcinoma.
- Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma.
- Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma.
- Long non-coding RNA LINC01793 as a potential diagnostic biomarker of hepatitis B virus-related hepatocellular carcinoma.
- Diagnostic value of long noncoding RNA LINC01485 in patients with colorectal cancer.
- Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
- PSMB5 overexpression is correlated with tumor proliferation and poor prognosis in hepatocellular carcinoma.
- A cohesin-associated gene score may predict immune checkpoint blockade in hepatocellular carcinoma.
- Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis.
- A novel Peng's test in reducing bile leakage after partial hepatectomy for hepatocellular carcinoma: From an animal study to a clinical cohort Propensity score matching comparative study.
- UBR7 inhibits HCC tumorigenesis by targeting Keap1/Nrf2/Bach1/HK2 and glycolysis.
- EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma.
- Multimodal imaging in hepatocellular carcinoma with inferior vena cava and right atrial tumor thrombus.
- Construction of a 3-mRNA hypoxia prognostic model to evaluate immune microenvironment in hepatocellular carcinoma.
- Gene mining of immune microenvironment in hepatocellular carcinoma.
- Bioinformatics analysis and experimental verification of five metabolism-related lncRNAs as prognostic models for hepatocellular carcinoma.
- Expression of IER3 in hepatocellular carcinoma: clinicopathology, prognosis, and potential regulatory pathways.
- Testis-specific protein Y-encoded 1 regulates androgen receptor expression through the MAPK/ERK pathway in male hepatocellular carcinoma.
- Radiomics and nomogram of magnetic resonance imaging for preoperative prediction of microvascular invasion in small hepatocellular carcinoma.
- Callispheres® drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients.
- Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt.
- Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma.
- Effect of timing of surgical resection of primary hepatocellular carcinoma on survival outcomes in elderly patients and prediction of clinical models.
- Hypomethylation-driven overexpression of HJURP promotes progression of hepatocellular carcinoma and is associated with poor prognosis.
- Expression, prognosis value, and immune infiltration of lncRNA ASB16-AS1 identified by pan-cancer analysis.
- Clinical significance and molecular mechanism of angiotensin-converting enzyme 2 in hepatocellular carcinoma tissues.
- Integrated multi-omics analysis of the clinical relevance and potential regulatory mechanisms of splicing factors in hepatocellular carcinoma.
- Down-regulation of microRNA-125b-2-3p is a risk factor for a poor prognosis in hepatocellular carcinoma.
- Identifying the Prognostic Risk Factors of Synaptojanin 2 and Its Underlying Perturbations Pathways in Hepatocellular Carcinoma.
- Preoperative combi-elastography for the prediction of early recurrence after curative resection of hepatocellular carcinoma.
- DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features.
- LINC00680 enhances hepatocellular carcinoma stemness behavior and chemoresistance by sponging miR-568 to upregulate AKT3.
- Hepatic Arterioportal Fistula Is Associated with Decreased Future Liver Remnant Regeneration after Stage-I ALPPS for Hepatocellular Carcinoma.
- Expression of Cell Division Cycle Protein 45 in Tissue Microarrays and the CDC45 Gene by Bioinformatics Analysis in Human Hepatocellular Carcinoma and Patient Outcomes.
- Signature of prognostic epithelial-mesenchymal transition related long noncoding RNAs (ERLs) in hepatocellular carcinoma.
- The diagnostic performance of gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced ultrasound in detecting hepatocellular carcinoma: A meta-analysis.
- Identification of potential biomarkers of peripheral blood mononuclear cell in hepatocellular carcinoma using bioinformatic analysis: A protocol for systematic review and meta-analysis.
- Efficacy of the association liver partition and portal vein ligation for staged hepatectomy for the treatment of solitary huge hepatocellular carcinoma: a retrospective single-center study.
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
- Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- A Study of DC-CIK to Treat Hepatocellular Carcinoma
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
- TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev
- A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
- YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC
- Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 46 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
南宁有 2 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- 分期
- 不分期
- 开始
- 2026-06
- 登记号
- NCT07552402
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文46
- Development and Validation of an AI-Based Multimodal Model for Pathological Staging of Gastric Cancer Using CT and Endoscopic Images.
- Comprehensive multi-omics pan-cancer analysis revealed EGFLAM as a potential prognostic and immune infiltration-associated biomarker.
- Comparison of outcomes between surgery and non-surgery after conversion therapy for advanced gastric cancer with unresectable factors: a systematic review and meta-analysis.
- Unveiling the heterogeneity and immunotherapy potency of tumor-associated neutrophils in the tumor microenvironment of gastric cancer.
- Transcription Factor MYB Upregulates IQGAP3 to Mediate DNA Repair and Promote 5-FU Resistance in Gastric Cancer Cells.
- Exploring NUP62's role in cancer progression, tumor immunity, and treatment response: insights from multi-omics analysis.
- CLIC1 regulates cellular oxidative stress and gastric cancer progress by enhancing ACOX1 ubiquitination.
- Exosome-derived Menin from cancer-associated fibroblasts promotes gastric cancer progression by activating the HSPA6/JNK/JunD pathway and inducing EMT.
- The CLIC1-PKM2 axis orchestrates glycolytic metabolism to accelerate gastric cancer progression.
- Body Composition Decrease and Impact on Clinical Outcome in Gastric Cancer Patients Undergoing Radical Gastrectomy After Neoadjuvant Treatment.
- Integrating visceral protein ratios and mid-arm circumference predicts survival and malnutrition in gastric cancer.
- Prognostic significance of anthropometric measurements in gastric cancer: a multicenter cohort study.
- CLIC1-mediated autophagy confers resistance to DDP in gastric cancer.
- Tislelizumab plus chemotherapy is an optimal option for second-line treatment for advanced gastroesophageal junction adenocarcinoma.
- A nomogram for predicting nutritional risk before gastric cancer surgery.
- Development and validation of a Radiopathomics model based on CT scans and whole slide images for discriminating between Stage I-II and Stage III gastric cancer.
- Human blood metabolites and gastric cancer: a Mendelian randomization analysis.
- Identification of CERS5 as a molecular biomarker in pan-cancer through multiple omics integrative analysis.
- Predicting malnutrition in gastric cancer patients using computed tomography(CT) deep learning features and clinical data.
- Anoikis-related genes as potential prognostic biomarkers in gastric cancer: A multilevel integrative analysis and predictive therapeutic value.
- Predictive value of prognostic nutritional index in patients undergoing gastrectomy for gastric cancer: A systematic review and meta-analysis.
- Prevalence and unfavorable outcome of frailty in older adults with gastric cancer: a systematic review and meta-analysis.
- Application of the quality of recovery-40 questionnaire to evaluate the effectiveness of enhanced recovery after surgery protocols in gastric cancer.
- Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer.
- Elian granules alleviate precancerous lesions of gastric cancer in rats by suppressing M2-type polarization of tumor-associated macrophages through NF-κB signaling pathway.
- Construction of an autophagy-related eleven long noncoding RNA signature to predict the outcomes, immune cell infiltration, and immunotherapy response in patients with gastric cancer.
- Pan-cancer analysis of the prognostic significance and oncogenic role of GXYLT2.
- Feasibility of olfactomedin 4 as a molecular biomarker for early diagnosis of gastric neoplasia after intestinal metaplasia.
- Comparison of clinical-computed tomography model with 2D and 3D radiomics models to predict occult peritoneal metastases in advanced gastric cancer.
- Radiomics in Addition to Computed Tomography-Based Body Composition Nomogram May Improve the Prediction of Postoperative Complications in Gastric Cancer Patients.
- DEAD-box helicase 56 functions as an oncogene promote cell proliferation and invasion in gastric cancer via the FOXO1/p21 Cip1/c-Myc signaling pathway.
- Tumor-derived extracellular vesicles shuttle c-Myc to promote gastric cancer growth and metastasis via the KCNQ1OT1/miR-556-3p/CLIC1 axis.
- Comment on Granieri et al. "Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: A meta-analysis of randomized controlled trials".
- Association of polymorphisms in PIN1 with progression and susceptibility in gastric cancer.
- Circ_0008287 promotes immune escape of gastric cancer cells through impairing microRNA-548c-3p-dependent inhibition of CLIC1.
- ITGA5 Promotes Tumor Progression through the Activation of the FAK/AKT Signaling Pathway in Human Gastric Cancer.
- Mechanism of Elian granules in the treatment of precancerous lesions of gastric cancer in rats through the MAPK signalling pathway based on network pharmacology.
- Construction of a novel signature and prediction of the immune landscape in gastric cancer based on necroptosis-related genes.
- Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer.
- SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation.
- The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials.
- Diagnostic Values of the Prealbumin-to-Fibrinogen, Albumin-to-Fibrinogen, and Monocyte-to-Lymphocyte Ratios in Gastric Cancer.
- α-Actinin1 promotes tumorigenesis and epithelial-mesenchymal transition of gastric cancer via the AKT/GSK3β/β-Catenin pathway.
- CLIC1 knockout inhibits invasion and migration of gastric cancer by upregulating AMOT-p130 expression.
- Integrated analysis identifies oxidative stress genes associated with progression and prognosis in gastric cancer.
- Effects of Laparoscopic Radical Gastrectomy on Peritoneal Micrometastases of Gastric Cancer.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
癌症
肝母细胞瘤
Hepatoblastoma2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。
这些数字背后的记录
癌症
脊索瘤
Chordoma2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 37 篇,占 1.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 12 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文37
- GSH-responsive Pt-based nanomotor with improved doxorubicin delivery for synergistic osteosarcoma chemotherapy.
- N-terminal histone acetyltransferase NAA40 modulates osteosarcoma progression by controlling AGR2 expression.
- Hsa_circ_0002005 aggravates osteosarcoma by increasing cell proliferation, migration, and invasion.
- NFATC3 enhances osteosarcoma progression by increasing PD-L1 and CXCL2 levels.
- Formononetin enhances cisplatin chemotherapy sensitivity in osteosarcoma by inducing ferroptosis and reconstructing the immune microenvironment.
- Prognostic significance of T cells and NK cells in osteosarcoma: a dual-center retrospective study.
- Single-cell and spatial transcriptomics reveal metastasis mechanism and microenvironment remodeling of lymph node in osteosarcoma.
- A Case of Non-calcified Intrahepatic Primary Osteosarcoma: A Case Report and a Literature Review.
- Development of a Risk Model and Genotyping Patterns Based on Disulfidptosis-Related lncRNAs to Predict Prognosis and Immune Landscape in Osteosarcoma.
- Development and validation of neutrophil extracellular traps-derived signature to predict the prognosis for osteosarcoma patients.
- Investigation of cellular communication and signaling pathways in tumor microenvironment for high TP53-expressing osteosarcoma cells through single-cell RNA sequencing.
- Identification and verification of a BMPs-related gene signature for osteosarcoma prognosis prediction.
- Pan-Cancer analysis of TERT and Validation in Osteosarcoma Cell Lines.
- Hsa_circ_0007031 promotes the proliferation and migration of osteosarcoma cells by sponging miR-196a-5p to regulate the HOXB6.
- FAM60A promotes osteosarcoma development and progression.
- Interaction gene set between osteoclasts and regulatory CD4+ T cells can accurately predict the prognosis of patients with osteosarcoma.
- Circ_0001060 Upregulates and Encourages Progression in Osteosarcoma.
- A new insight of immunosuppressive microenvironment in osteosarcoma lung metastasis.
- Analysis of scRNA-seq and bulk RNA-seq demonstrates the effects of EVI2B or CD361 on CD8+ T cells in osteosarcoma.
- A novel molecular signature for predicting prognosis and immunotherapy response in osteosarcoma based on tumor-infiltrating cell marker genes.
- Exosome-mediated miR-144-3p promotes ferroptosis to inhibit osteosarcoma proliferation, migration, and invasion through regulating ZEB1.
- Long non-coding RNA and circular RNA and coding RNA profiling of plasma exosomes of osteosarcoma by RNA seq.
- RhRu Alloy-Anchored MXene Nanozyme for Synergistic Osteosarcoma Therapy.
- Efficacy of Diffusion-Weighted Imaging in Neoadjuvant Chemotherapy for Osteosarcoma: A Systematic Review and Meta-Analysis.
- A new model of preoperative systemic inflammatory markers predicting overall survival of osteosarcoma: a multicenter retrospective study.
- Significance of the neutrophil-to-lymphocyte ratio in predicting the response to neoadjuvant chemotherapy in extremity osteosarcoma: a multicentre retrospective study.
- PLCE1 is a poor prognostic marker and may promote immune escape from osteosarcoma by the CD70-CD27 signaling pathway.
- Identification of Candidate MicroRNA-mRNA Subnetwork for Predicting the Osteosarcoma Progression by Bioinformatics Analysis.
- Construction of a transcription factor-miRNA-mRNA interactive network elucidates underlying pathogenesis for osteosarcoma and validation by qRT-PCR.
- Prognostic value of preoperative P-CRP in patients with osteosarcoma: A retrospective study of 101 cases.
- Two novel predictive biomarkers for osteosarcoma and glycolysis pathways: A profiling study on HS2ST1 and SDC3.
- The regulatory mechanism of LncRNA-mediated ceRNA network in osteosarcoma.
- Five hypoxia and immunity related genes as potential biomarkers for the prognosis of osteosarcoma.
- Current research progress in targeted anti-angiogenesis therapy for osteosarcoma.
- STAT3 and its targeting inhibitors in osteosarcoma.
- CCT6A, a novel prognostic biomarker for Ewing sarcoma.
- TYROBP, TLR4 and ITGAM regulated macrophages polarization and immune checkpoints expression in osteosarcoma.
早期论文(2016–2020 年)16
- Intraperitoneal extraosseous osteosarcoma: a case report and literatures review.
- m6A-dependent up-regulation of DRG1 by METTL3 and ELAVL1 promotes growth, migration, and colony formation in osteosarcoma.
- Berberine enhances the radiosensitivity of osteosarcoma by targeting Rad51 and epithelial-mesenchymal transition.
- URG4 mediates cell proliferation and cell cycle in osteosarcoma via GSK3β/β-catenin/cyclin D1 signaling pathway.
- Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients.
- Impact of Hydrogel Elasticity and Adherence on Osteosarcoma Cells and Osteoblasts.
- Untangling the response of bone tumor cells and bone forming cells to matrix stiffness and adhesion ligand density by means of hydrogels.
- Differential expression and bioinformatics analysis of circRNA in osteosarcoma.
- Expression of miR‑542‑3p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.
- [Application of pasteurized tumor-bearing bone replantation for primary malignant bone tumor of extremities].
- To Explore the Mechanism of the GRM4 Gene in Osteosarcoma by RNA Sequencing and Bioinformatics Approach.
- Acute lymphoblastic leukemia arising after treatment of Ewing sarcoma was misdiagnosed as bone marrow metastasis of Ewing sarcoma: A case report.
- Long non-coding RNA HOXA11-AS functions as a competing endogenous RNA to regulate ROCK1 expression by sponging miR-124-3p in osteosarcoma.
- Icarisid II inhibits the proliferation of human osteosarcoma cells by inducing apoptosis and cell cycle arrest.
- Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control.
- Association of GRM4 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma in Guangxi Chinese population.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 3 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文3
- Computed tomography-guided microwave ablation therapy for pediatric adrenal neuroblastoma with lung nodule a case report.
- Competing endogenous RNA network analysis of the molecular mechanisms of ischemic stroke.
- MLKL regulates Cx43 ubiquitinational degradation and mediates neuronal necroptosis in ipsilateral thalamus after focal cortical infarction.
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 3 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 11 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
南宁有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 5
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-02
- 登记号
- NCT07258511
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心北京、南京、南宁、成都、杭州、武汉、温州、西安
- 正在招募Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- 分期
- 未注明
- 开始
- 2026-06
- 登记号
- NCT07663253
年龄 18 岁 至 未注明(登记的条件)
牵头:复旦大学附属中山医院;另有 9 家列出的医院为研究中心上海、北京、南宁、南通、广州、成都、昆明、武汉、西安、郑州
- 正在招募A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- 分期
- I/II期
- 开始
- 2024-07
- 登记号
- NCT06083207
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 9 家列出的医院为研究中心上海、北京、南京、南宁、天津、徐州、武汉、苏州、西安
- 正在招募A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- 分期
- III期
- 开始
- 2022-10
- 登记号
- NCT05552222
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙
- 即将招募Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 登记号
- NCT07569757
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文11
- Active Epstein-Barr virus infection and its association with multiple myeloma: evidence from a meta-analytical perspective.
- Beyond ISS staging: the prognostic value of the Inflammation Prognostic Score Index (IPSI) in multiple myeloma.
- Visual assessment and quantitative analysis of dual-energy CT virtual non-calcium in imaging diagnosis of multiple myeloma.
- Association between BCL2 interacting protein 3 like (BNIP3L) genetic polymorphisms and the risk of multiple myeloma in China.
- Correlation analysis of laboratory indicators, genetic abnormalities and staging in patients with newly diagnosed multiple myeloma.
- Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: a systematic review and meta-analysis.
- 5-Amino-4-Imidazolecarboxamide Ribonucleotide Transformylase/IMP Cyclohydrolase Polymorphisms Affect the Susceptibility to Multiple Myeloma.
- MiR-197-3p reduces bortezomib resistance in multiple myeloma by inhibiting IL-6 expression in a MEAF6-dependent manner.
- Upregulation of ATIC in multiple myeloma tissues based on tissue microarray and gene microarrays.
- Integrated analysis of hub gene expression in multiple myeloma.
- Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
- Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
血液疾病
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的噬血细胞性淋巴组织细胞增生症开放试验。
这些数字背后的记录
牵头的论文3
- Sintilimab combined with chidamide in the treatment of extranodal nature killer/T-cell lymphoma with secondary hemophagocytic lymphohistiocytosis: Two case reports and literature review.
- Intrathoracic infections in Hodgkin lymphoma (HL) patients may cooperate with HL to trigger hemophagocytic lymphohistiocytosis: A retrospective study.
- Intrapleural infections in patients with subcutaneous panniculitis-like T-cell lymphoma are susceptible to hemophagocytic lymphohistiocytosis.
血液疾病
β 地中海贫血
Beta thalassaemia2021–2025 年中国大陆作者发表的 312 篇β 地中海贫血 PubMed 英文论文中,这家医院牵头了 25 篇,占 8.0%。
南宁有 9 家医院列在β 地中海贫血下全国有 157 家医院列在β 地中海贫血下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
- 分期
- 早期I期
- 开始
- 2023-02
- 登记号
- NCT05762510
年龄 5 岁 至 35 岁(登记的条件)
牵头:广西医科大学第一附属医院;另有 1 家列出的医院为研究中心南宁
- 正在招募A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- 分期
- I期
- 开始
- 2024-01
- 登记号
- NCT06465550
年龄 3 岁 至 35 岁(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、南宁、广州
- 正在招募A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
- 分期
- I期
- 开始
- 2024-12
- 登记号
- NCT06772766
年龄 18 岁 至 65 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心南宁、海口
- 正在招募Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- 分期
- II期
- 开始
- 2019-11
- 登记号
- NCT04143724
年龄 6 岁 至 17 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心南宁、广州、成都、深圳
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文25
- WGCNA and LASSO regression-based selection and validation of microRNA biomarkers of β-thalassemia.
- Whole-Brain Analysis of Increased Brain Iron in Patients with β-Thalassemia.
- Neuroimaging in the diagnosis and treatment of cerebral toxoplasmosis in children with severe β-thalassemia after allo-HSCT.
- Study on Large-Scale Brain Network Abnormalities in Patients With Beta-Thalassemia.
- Echocardiographic Left Atrial Stiffness Index Predicts Myocardial Iron Overload in Pediatric β-Thalassemia.
- Predictive value of hepcidin and HIF1α protein levels for iron deposition in β-thalassemia.
- Risk factors of low bone mass in young patients with transfusion-dependent beta-thalassemia.
- IGHG4: innovative diagnostic biomarkers for iron overload in β-thalassemia patients.
- KLF1 Knockdown Differentially Regulates γ-Globin Expression: Inhibition in K562 Cells but Reactivation in β-Thalassemia Major Erythrocytes with Erythropoiesis Disruption.
- Research on iron regulatory erythroid factors in children with β-thalassemia.
- Correlation study between magnetic resonance imaging-quantitated cardiac iron deposition and left ventricular function in patients with β-thalassemia major in China.
- White matter microstructure abnormalities in thalassemia patients using TBSS analysis based on DTI.
- Research on the clinical factors of cardiac iron deposition in children with beta-thalassemia major.
- Long-term Effect of Hematopoietic Stem Cell Transplantation on the Quality of Life of Patients with β-thalassemia Major in Guangxi, China - A Cross-sectional Study.
- Identification of two novel β-globin gene mutations HBB: exon3del, HBB: c.-81A>C.
- Molecular Basis and Hematologic Phenotype of Hemoglobin H Disease Combined with Two Rare β-Globin Mutations.
- Integration of targeted sequencing and pseudo-tetraploid genotyping into clinically assisted decision support for β-thalassemia invasive prenatal diagnosis.
- Magnetic resonance imaging assessment of the changes of cardiac and hepatic iron load in thalassemia patients before and after hematopoietic stem cell transplantation.
- Echocardiographic evaluation of left atrial strain for predicting iron overload in pediatric patients with β-thalassemia with preserved ejection fraction.
- Health-related quality of life in pediatric patients with β-thalassemia major after hematopoietic stem cell transplantation.
- Analysis of circRNAs and circRNA-associated competing endogenous RNA networks in β-thalassemia.
- Hepatic veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation for thalassemia major: incidence, management, and outcome.
- Quality of Life in Patients with β-thalassemia Major: Short-term and Long-term Effects After Haematopoietic Stem Cell Transplantation.
- Spectrum of β-Thalassemia Mutations in Some Areas of Guangxi Zhuang Autonomous Region of Southern China: A Study on a Pediatric Population Aged 0-15 Years.
- Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics.
早期论文(2016–2020 年)15
- A 15-years follow-up of deferasirox in beta-thalassaemia major patients with iron overload.
- Hereditary spherocytosis overlooked for 7 years in a pediatric patient with β-thalassemia trait and novel compound heterozygous mutations of SPTA1 gene.
- Compound Heterozygosity for a Novel Mutation Codon 104 (-A) (HBB: c.313delA) and Codons 41/42 (-CTTT) (HBB: c.126_129delCTTT) Leading to β-Thalassemia Major in a Chinese Family.
- A Novel Mutation at HBB: c.91delA (Codon 30, -A) Causing β-Thalassemia in a Chinese Family.
- G-CSF-Mobilized Blood and Bone Marrow Grafts as the Source of Stem Cells for HLA-Identical Sibling Transplantation in Patients with Thalassemia Major.
- Immune recovery after in vivo T-cell depletion myeloablative conditioning hematopoietic stem cell transplantation in severe beta-thalassemia children.
- Construction and Analysis of a Long Non-Coding RNA (lncRNA)-Associated ceRNA Network in β-Thalassemia and Hereditary Persistence of Fetal Hemoglobin.
- BCL11A Down-Regulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells.
- ARHGAP18 is a novel gene under positive natural selection that influences HbF levels in β-thalassaemia.
- Alterations of anticoagulant proteins and soluble endothelial protein C receptor in thalassemia patients of Chinese origin.
- SOX6 Downregulation Induces γ-Globin in Human β-Thalassemia Major Erythroid Cells.
- A Novel Variant with Positive Natural Selection Influenced Hb A2 Levels in Chinese Individuals with β-Thalassemia.
- Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated co-expression and ceRNA networks in β-thalassemia and hereditary persistence of fetal hemoglobin.
- The prevalence of thalassemia in mainland China: evidence from epidemiological surveys.
- Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
它在 ClinicalTrials.gov 上的全部试验(任何状态)15
- A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
- A Pilot Study on the Safety and Efficacy of YOLT-204 for Transfusion-Dependent Beta-Thalassemia
- Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
- Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
- Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism
- A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
- A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
- Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
- A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major
- A Long-term Follow-up Study in Participants Who Received CS-101
- A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection
- A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major
- CS-101 in Patients With β-thalassemia
- A Clinical Study Evaluating the Safety and Efficacy of CS-101 in Treating Subjects With β-thalassemia
- Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 2 家医院列在血友病 A下全国有 160 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.6%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的视神经脊髓炎谱系疾病开放试验。
这些数字背后的记录
牵头的论文3
- A comparative study of hypothalamic involvement in patients with myelin oligodendrocyte glycoprotein antibody-associated disease, neuromyelitis optica spectrum disorder, and multiple sclerosis.
- The impact of COVID-19 on a Southern Chinese cohort with neuromyelitis optica spectrum disorders.
- Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文5
- miR-125a-5p regulates Treg function by targeting Foxp3 in experimental autoimmune myasthenia gravis mice.
- FcRn inhibition with efgartigimod ameliorates muscle weakness and modulates dendritic cell subsets in an experimental autoimmune myasthenia gravis mouse model.
- The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study.
- DCAF12 and HSPA1A May Serve as Potential Diagnostic Biomarkers for Myasthenia Gravis.
- Autophagy-deficiency in bone marrow mononuclear cells from patients with myasthenia gravis: a possible mechanism of pathogenesis.
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。
这些数字背后的记录
牵头的论文4
- Association of peripheral blood inflammatory biomarkers and poor clinical outcomes in adult stroke patients with moyamoya disease.
- Efficacy of double-barrel versus single-branch superficial temporal artery-middle cerebral artery bypass in the treatment of moyamoya disease: Does double-barrel bypass offer any advantages?
- Bilateral carotid and vertebral rete mirabile with aneurysm misdiagnosed as Moyamoya disease: A case report.
- Predictive Factors for Seizures after Revascularization in Patients with Moyamoya Disease.
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 11 篇,占 4.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 2 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文11
- Elevated Release of Presynaptic Glutamate: The Potential Pathogenesis of Anti-NMDAR Encephalitis-Associated Seizures.
- Abnormal global and local connectivity in patients with anti-N-methyl-D-aspartate receptor encephalitis: A resting-state functional MRI study.
- Identifying the Anti-inflammatory Effects of Astragalus Polysaccharides in Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Network Pharmacology and Experimental Validation.
- The P38MAPK Pathway Mediates the Destruction of the Blood-Brain Barrier in Anti-NMDAR Encephalitis Mice.
- Abnormalities in modular connectivity of functional brain networks and cognitive changes in patients with anti -N-methyl-D-aspartate receptor encephalitis.
- Inhibiting PI3K/Akt-Signaling Pathway Improves Neurobehavior Changes in Anti-NMDAR Encephalitis Mice by Ameliorating Blood-Brain Barrier Disruption and Neuronal Damage.
- The alterations of spontaneous neural activities and white matter microstructures in anti-N-methyl-D-aspartate receptor encephalitis: a resting-state fMRI and DTI study.
- Correlation analysis between regional homogeneity and executive dysfunction in anti-N-methyl-D-aspartate receptor encephalitis patients.
- Aberrant resting-state interhemispheric functional connectivity in patients with anti-N-methyl-D-aspartate receptor encephalitis.
- The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity.
- Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor encephalitis: a retrospective, multicenter, self-controlled study.
早期论文(2016–2020 年)3
- Cerebral functional activity and connectivity changes in anti-N-methyl-D-aspartate receptor encephalitis: A resting-state fMRI study.
- Voxel-based analysis and multivariate pattern analysis of diffusion tensor imaging study in anti-NMDA receptor encephalitis.
- Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 2 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
南宁有 2 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
早期论文(2016–2020 年)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.9%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 2 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
白塞病
Behçet disease2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 4 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文4
- Machine-learning model based on ultrasomics for non-invasive evaluation of fibrosis in IgA nephropathy.
- Correlation analysis of cofilin-1 with renal prognosis in primary IgA nephropathy.
- Characteristics and function of the gut microbiota in patients with IgA nephropathy via metagenomic sequencing technology.
- Expression of GADD45B in Renal Tissue of Children with IgA Nephropathy and Correlation with Mesangial Hypercellularity.
早期论文(2016–2020 年)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 2 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
南宁有 1 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- 分期
- III期
- 开始
- 2025-12
- 登记号
- NCT07282353
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
- The clinical value of the monocyte to high-density lipoprotein cholesterol ratio and alkaline phosphatase-to-platelet ratio in primary biliary cholangitis.
- Diagnostic and Prognostic Value of Monocyte-to-Lymphocyte Ratio and Red Cell Distribution Width to Lymphocyte Ratio in Primary Biliary Cholangitis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 1 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性硬化性胆管炎开放试验。
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年没有牵头家族性腺瘤性息肉病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
南宁有 2 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
联系这家医院
出示给工作人员或司机的院名卡
广西医科大学第一附属医院
First Affiliated Hospital of Guangxi Medical University
南宁
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药